Details of the Drug

General Information of Drug (ID: DMS1YPZ)

Drug Name

SAR391786

Indication

Disease Entry	ICD 11	Status	REF
Muscle atrophy	FB32.Y	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth/differentiation factor 8 (GDF-8)	TTSWPH8	GDF8_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Muscle atrophy

ICD Disease Classification

FB32.Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Growth/differentiation factor 8 (GDF-8)	DTT	MSTN	1.64E-01	-0.06	-0.06

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01963598) Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia. U.S. National Institutes of Health.
2	Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63.